- Patent Title: Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies
-
Application No.: US13322863Application Date: 2010-05-27
-
Publication No.: US09989533B2Publication Date: 2018-06-05
- Inventor: Zhenggang Liu
- Applicant: Zhenggang Liu
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
- Current Assignee Address: US DC Washington
- Agency: Locke Lord LLP
- Agent Bryan D. Zerhusen
- International Application: PCT/US2010/036394 WO 20100527
- International Announcement: WO2010/138709 WO 20101202
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/574 ; C07K14/47 ; C07K14/82
Abstract:
The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). ATIA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The invention encompasses combination therapies where knockdown of ATIA is used in combination with other treatment. The invention also features kits for use in the diagnostic and therapeutic methods.
Public/Granted literature
- US20120082660A1 ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES Public/Granted day:2012-04-05
Information query
IPC分类:
